Stream Link: https://event.arraylive.com/app/login/95fc3aa2-86e6-4056-a170-be0287b53d47/virtualattendee
Program Information
Metabolic dysfunction-associated steatohepatitis (MASH) is a severe, inflammatory form of liver disease associated with various metabolic comorbidities, such as type 2 diabetes and obesity. A growing understanding of disease pathogenesis has contributed to the emergence and recent therapy approvals, including THR-β agonists and GLP-1 receptor agonists, that target fibrotic and metabolic pathways. As the prevalence of MASH continues to rise alongside an evolving treatment landscape, pharmacists are positioned to provide and optimize comprehensive care for patients with MASH. This activity will discuss disease-modifying intervention strategies to reduce the clinical burden associated with MASH, emphasizing the early identification and management of underlying cardiometabolic risk factors. Challenges navigating access to MASH therapies, key patient counseling considerations related to lifestyle modifications and medication use, and approaches to coordinating safe multidisciplinary care will be addressed to support improved patient outcomes.
Target audience: Specialty Pharmacists, Health-System Pharmacists
Type of activity: Application
Release date: May 21, 2026
Expiration date: July 21, 2026
Time to complete activity: 1 hour
Learner level: Foundational
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Explain MASH, its incidence, risk factors, clinical presentation, and association with poor health outcomes.
- Apply current guideline recommendations for the screening, identification, and treatment of MASLD and MASH.
- Examine the efficacy and safety of currently available therapies for the treatment of MASH.
- Identify the role of the pharmacist in improving care and outcomes for patients with MASLD and MASH.
